These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 31123830)
1. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism. Cariello M; Piglionica M; Gadaleta RM; Moschetta A Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830 [TBL] [Abstract][Full Text] [Related]
2. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19. Piglionica M; Cariello M; Moschetta A Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181 [TBL] [Abstract][Full Text] [Related]
3. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis. Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200 [TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. Gadaleta RM; Garcia-Irigoyen O; Cariello M; Scialpi N; Peres C; Vetrano S; Fiorino G; Danese S; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A EBioMedicine; 2020 Apr; 54():102719. PubMed ID: 32259714 [TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling. Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979 [TBL] [Abstract][Full Text] [Related]
6. Roles of FGF19 in liver metabolism. Kir S; Kliewer SA; Mangelsdorf DJ Cold Spring Harb Symp Quant Biol; 2011; 76():139-44. PubMed ID: 21813638 [TBL] [Abstract][Full Text] [Related]
7. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations. Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883 [TBL] [Abstract][Full Text] [Related]
8. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724 [TBL] [Abstract][Full Text] [Related]
9. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907 [TBL] [Abstract][Full Text] [Related]
10. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580 [TBL] [Abstract][Full Text] [Related]
11. Developmental regulation of the intestinal FGF19 system in domestic pigs. Gavaldà-Navarro A; Pastor JJ; Mereu A; Villarroya F; Ipharraguerre IR Am J Physiol Gastrointest Liver Physiol; 2018 Jun; 314(6):G647-G654. PubMed ID: 29446652 [TBL] [Abstract][Full Text] [Related]
12. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence. Simbrunner B; Hofer BS; Schwabl P; Zinober K; Petrenko O; Fuchs C; Semmler G; Marculescu R; Mandorfer M; Datz C; Trauner M; Reiberger T Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428 [TBL] [Abstract][Full Text] [Related]
13. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome. Johansson H; Svensson JF; Almström M; Van Hul N; Rudling M; Angelin B; Nowak G; Fischler B; Ellis E J Intern Med; 2020 May; 287(5):534-545. PubMed ID: 31976601 [TBL] [Abstract][Full Text] [Related]
14. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475 [TBL] [Abstract][Full Text] [Related]
15. Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates. Memon N; Griffin IJ; Lee CW; Herdt A; Weinberger BI; Hegyi T; Carayannopoulos MO; Aleksunes LM; Guo GL J Matern Fetal Neonatal Med; 2020 Mar; 33(6):987-992. PubMed ID: 30122083 [No Abstract] [Full Text] [Related]
16. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis. Wu X; Li Y Aging (Albany NY); 2009 Dec; 1(12):1023-7. PubMed ID: 20157585 [TBL] [Abstract][Full Text] [Related]
17. Tissue-specific mechanisms of bile acid homeostasis and activation of FXR-FGF19 signaling in preterm and term neonatal pigs. Vonderohe C; Guthrie G; Stoll B; Chacko S; Dawson H; Burrin DG Am J Physiol Gastrointest Liver Physiol; 2022 Jan; 322(1):G117-G133. PubMed ID: 34851728 [TBL] [Abstract][Full Text] [Related]
18. Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A. Jahn D; Sutor D; Dorbath D; Weiß J; Götze O; Schmitt J; Hermanns HM; Geier A Biochim Biophys Acta; 2016 Feb; 1859(2):381-92. PubMed ID: 26723851 [TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Mellor HR Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342 [TBL] [Abstract][Full Text] [Related]
20. A gut-brain axis regulating glucose metabolism mediated by bile acids and competitive fibroblast growth factor actions at the hypothalamus. Liu S; Marcelin G; Blouet C; Jeong JH; Jo YH; Schwartz GJ; Chua S Mol Metab; 2018 Feb; 8():37-50. PubMed ID: 29290621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]